Menu

Report Library

All Reports

Financing Quarterly Statistics, Q3 2024

November 06, 2024

During Q3, biopharmas brought in an aggregate $17bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.1m.

Disease Group Covered: Allergy
Autoimmune/immunology
Cardiovascular
Dermatology
Endocrine
ENT/Dental
Gastroenterology (Non Inflammatory Bowel Disease)
Hematology
Infectious Disease
Metabolic
Neurology
Not Specified
Obstetrics/Gynecology
Oncology
Ophthalmology
Orthopedics
Psychiatry
Renal
Respiratory
Rheumatology (Non Autoimmune)
Urology